Endogenous nitric oxide attenuates neutrally mediated cutaneous vasoconstriction

Manabu Shibasaki, Sylvain Durand, Scott L. Davis, Jian Cui, David A. Low, David M. Keller, Craig G. Crandall

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Cutaneous vasoconstrictor responsiveness may be impaired by substance(s) directly or indirectly responsible for cutaneous active vasodilatation. In this study, we tested the hypothesis that endogenous nitric oxide (NO) attenuates the reduction in cutaneous vascular conductance (CVC) during an orthostatic challenge combined with whole-body heating, as well as during whole-body cooling. In protocol 1, healthy subjects were pretreated with an intradermal injection of botulinum toxin A (BTX) to block the release of neurotransmitters from nerves responsible for cutaneous active vasodilatation. On the experimental day, a microdialysis probe was placed at the BTX-treated site as well as at two adjacent untreated sites. NG-nitro-L-arginine methyl ester (L-NAME, 10 mM) was perfused through the probe placed at the BTX-treated site and at one untreated site. After confirmation of the absence of cutaneous vasodilatation at the BTX site during whole-body heating, adenosine was infused through the microdialysis probe at this site to increase skin blood flow to a level similar to that at the untreated site. Subsequently, 30 and 40 mmHg lower-body negative pressures (LBNPs) were applied. The reduction in CVC to LBNP was greatest at the BTX-treated site (15.0 ± 2.4% of the maximum level (% max)), followed by the L-NAME-treated site (11.3 ± 2.6% max), and then the untreated site (3.8 ± 3.0% max; P < 0.05 for all comparisons). In protocol 2, two microdialysis membranes were inserted in the dermal space of one forearm. Adenosine alone was infused at one site while the other site received adenosine and L-NAME. The reduction in CVC in response to whole-body cooling was significantly greater at the L-NAME-treated site than at the adjacent adenosine alone site. These results suggest that endogenous NO is capable of attenuating cutaneous vasoconstrictor responsiveness.

Original languageEnglish (US)
Pages (from-to)627-634
Number of pages8
JournalJournal of Physiology
Volume585
Issue number2
DOIs
StatePublished - Dec 1 2007

Fingerprint

Vasoconstriction
Nitric Oxide
Skin
Type A Botulinum Toxins
NG-Nitroarginine Methyl Ester
Adenosine
Microdialysis
Vasodilation
Lower Body Negative Pressure
Blood Vessels
Vasoconstrictor Agents
Heating
Intradermal Injections
Forearm
Neurotransmitter Agents
Healthy Volunteers
Membranes

All Science Journal Classification (ASJC) codes

  • Physiology

Cite this

Shibasaki, M., Durand, S., Davis, S. L., Cui, J., Low, D. A., Keller, D. M., & Crandall, C. G. (2007). Endogenous nitric oxide attenuates neutrally mediated cutaneous vasoconstriction. Journal of Physiology, 585(2), 627-634. https://doi.org/10.1113/jphysiol.2007.144030
Shibasaki, Manabu ; Durand, Sylvain ; Davis, Scott L. ; Cui, Jian ; Low, David A. ; Keller, David M. ; Crandall, Craig G. / Endogenous nitric oxide attenuates neutrally mediated cutaneous vasoconstriction. In: Journal of Physiology. 2007 ; Vol. 585, No. 2. pp. 627-634.
@article{f622c8ea08704f3c8ade2a7420c3c4f7,
title = "Endogenous nitric oxide attenuates neutrally mediated cutaneous vasoconstriction",
abstract = "Cutaneous vasoconstrictor responsiveness may be impaired by substance(s) directly or indirectly responsible for cutaneous active vasodilatation. In this study, we tested the hypothesis that endogenous nitric oxide (NO) attenuates the reduction in cutaneous vascular conductance (CVC) during an orthostatic challenge combined with whole-body heating, as well as during whole-body cooling. In protocol 1, healthy subjects were pretreated with an intradermal injection of botulinum toxin A (BTX) to block the release of neurotransmitters from nerves responsible for cutaneous active vasodilatation. On the experimental day, a microdialysis probe was placed at the BTX-treated site as well as at two adjacent untreated sites. NG-nitro-L-arginine methyl ester (L-NAME, 10 mM) was perfused through the probe placed at the BTX-treated site and at one untreated site. After confirmation of the absence of cutaneous vasodilatation at the BTX site during whole-body heating, adenosine was infused through the microdialysis probe at this site to increase skin blood flow to a level similar to that at the untreated site. Subsequently, 30 and 40 mmHg lower-body negative pressures (LBNPs) were applied. The reduction in CVC to LBNP was greatest at the BTX-treated site (15.0 ± 2.4{\%} of the maximum level ({\%} max)), followed by the L-NAME-treated site (11.3 ± 2.6{\%} max), and then the untreated site (3.8 ± 3.0{\%} max; P < 0.05 for all comparisons). In protocol 2, two microdialysis membranes were inserted in the dermal space of one forearm. Adenosine alone was infused at one site while the other site received adenosine and L-NAME. The reduction in CVC in response to whole-body cooling was significantly greater at the L-NAME-treated site than at the adjacent adenosine alone site. These results suggest that endogenous NO is capable of attenuating cutaneous vasoconstrictor responsiveness.",
author = "Manabu Shibasaki and Sylvain Durand and Davis, {Scott L.} and Jian Cui and Low, {David A.} and Keller, {David M.} and Crandall, {Craig G.}",
year = "2007",
month = "12",
day = "1",
doi = "10.1113/jphysiol.2007.144030",
language = "English (US)",
volume = "585",
pages = "627--634",
journal = "Journal of Physiology",
issn = "0022-3751",
publisher = "Wiley-Blackwell",
number = "2",

}

Shibasaki, M, Durand, S, Davis, SL, Cui, J, Low, DA, Keller, DM & Crandall, CG 2007, 'Endogenous nitric oxide attenuates neutrally mediated cutaneous vasoconstriction', Journal of Physiology, vol. 585, no. 2, pp. 627-634. https://doi.org/10.1113/jphysiol.2007.144030

Endogenous nitric oxide attenuates neutrally mediated cutaneous vasoconstriction. / Shibasaki, Manabu; Durand, Sylvain; Davis, Scott L.; Cui, Jian; Low, David A.; Keller, David M.; Crandall, Craig G.

In: Journal of Physiology, Vol. 585, No. 2, 01.12.2007, p. 627-634.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Endogenous nitric oxide attenuates neutrally mediated cutaneous vasoconstriction

AU - Shibasaki, Manabu

AU - Durand, Sylvain

AU - Davis, Scott L.

AU - Cui, Jian

AU - Low, David A.

AU - Keller, David M.

AU - Crandall, Craig G.

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Cutaneous vasoconstrictor responsiveness may be impaired by substance(s) directly or indirectly responsible for cutaneous active vasodilatation. In this study, we tested the hypothesis that endogenous nitric oxide (NO) attenuates the reduction in cutaneous vascular conductance (CVC) during an orthostatic challenge combined with whole-body heating, as well as during whole-body cooling. In protocol 1, healthy subjects were pretreated with an intradermal injection of botulinum toxin A (BTX) to block the release of neurotransmitters from nerves responsible for cutaneous active vasodilatation. On the experimental day, a microdialysis probe was placed at the BTX-treated site as well as at two adjacent untreated sites. NG-nitro-L-arginine methyl ester (L-NAME, 10 mM) was perfused through the probe placed at the BTX-treated site and at one untreated site. After confirmation of the absence of cutaneous vasodilatation at the BTX site during whole-body heating, adenosine was infused through the microdialysis probe at this site to increase skin blood flow to a level similar to that at the untreated site. Subsequently, 30 and 40 mmHg lower-body negative pressures (LBNPs) were applied. The reduction in CVC to LBNP was greatest at the BTX-treated site (15.0 ± 2.4% of the maximum level (% max)), followed by the L-NAME-treated site (11.3 ± 2.6% max), and then the untreated site (3.8 ± 3.0% max; P < 0.05 for all comparisons). In protocol 2, two microdialysis membranes were inserted in the dermal space of one forearm. Adenosine alone was infused at one site while the other site received adenosine and L-NAME. The reduction in CVC in response to whole-body cooling was significantly greater at the L-NAME-treated site than at the adjacent adenosine alone site. These results suggest that endogenous NO is capable of attenuating cutaneous vasoconstrictor responsiveness.

AB - Cutaneous vasoconstrictor responsiveness may be impaired by substance(s) directly or indirectly responsible for cutaneous active vasodilatation. In this study, we tested the hypothesis that endogenous nitric oxide (NO) attenuates the reduction in cutaneous vascular conductance (CVC) during an orthostatic challenge combined with whole-body heating, as well as during whole-body cooling. In protocol 1, healthy subjects were pretreated with an intradermal injection of botulinum toxin A (BTX) to block the release of neurotransmitters from nerves responsible for cutaneous active vasodilatation. On the experimental day, a microdialysis probe was placed at the BTX-treated site as well as at two adjacent untreated sites. NG-nitro-L-arginine methyl ester (L-NAME, 10 mM) was perfused through the probe placed at the BTX-treated site and at one untreated site. After confirmation of the absence of cutaneous vasodilatation at the BTX site during whole-body heating, adenosine was infused through the microdialysis probe at this site to increase skin blood flow to a level similar to that at the untreated site. Subsequently, 30 and 40 mmHg lower-body negative pressures (LBNPs) were applied. The reduction in CVC to LBNP was greatest at the BTX-treated site (15.0 ± 2.4% of the maximum level (% max)), followed by the L-NAME-treated site (11.3 ± 2.6% max), and then the untreated site (3.8 ± 3.0% max; P < 0.05 for all comparisons). In protocol 2, two microdialysis membranes were inserted in the dermal space of one forearm. Adenosine alone was infused at one site while the other site received adenosine and L-NAME. The reduction in CVC in response to whole-body cooling was significantly greater at the L-NAME-treated site than at the adjacent adenosine alone site. These results suggest that endogenous NO is capable of attenuating cutaneous vasoconstrictor responsiveness.

UR - http://www.scopus.com/inward/record.url?scp=36649012967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36649012967&partnerID=8YFLogxK

U2 - 10.1113/jphysiol.2007.144030

DO - 10.1113/jphysiol.2007.144030

M3 - Article

C2 - 17947310

AN - SCOPUS:36649012967

VL - 585

SP - 627

EP - 634

JO - Journal of Physiology

JF - Journal of Physiology

SN - 0022-3751

IS - 2

ER -